• U.S. Department of Veterans Affairs White River Junction Medical Center Joins Medibio Depression Diagnostic Confirmatory Study to Support FDA Clearance

View Press Release PDF

• Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market Opportunities

View Press Release PDF

• Medibio’s Depression Diagnostic Ready for FDA Confirmatory Study. (Aug 2 2017)

• Medibio Initiates Enrollment for Its Depression Diagnostic Confirmatory Study to Support FDA Clearance (Aug 21 2017)

• Medibio signs strategic joint Development Agreement with Mayo Clinic.

• Appointment of Non Executive Director & Advisory Board Chang (1 Feb 2017)

• Medibio Appoints US and med-tech veteran as CEO and Managing Director (16 Feb 2017)

• App 3B (3 Nov 2016)

• University of Ottawa Depression Study improves accuracy rate to an outstanding 86% in a far larger sample.(Nov 16)

• Capital raising of $13.5 million to accelerate growth (Nov 16)

• Medibio Limited announces that Dr James Campbell has resigned as a Non-Executive Director of Medibio
• Medibio AGM Presentation (Nov 29)

• Trading Halt Request (5 Aug 2016)
• Depression Validation Results (August 2016)
• BMC Collaboration (17 Aug 2016)
• Investor Presentation (23 Aug 2016)
• Preliminary Final Report (31 Aug 2016)

• First Commercial Pilot (30 May 2016)

• Partnership to evaluate wearables (8 Feb 2016)
• First Wellness Channel Partner commercial pilot (16 Feb 2016)
• MEB Half Yearly Report and Accounts to 31 December 2015 (28 Feb 2016)

• MEB Quarterly Report for the period ending (30 Sep 2015)
• MEB’s Signs First Multinational Client (6 Nov 2015)
• MEB Foster Research Report (10 Nov 2015)
• MEB ASX Investor Series Presentation (17 Nov 2015)
• MEB Final JHU Release-IRB (ASX Release) (24 Nov 2015)
• MEB Corporate Wellness Partner Program Commences (26 Nov 2015)

• MEB June 2015 Quarter Operations Report (4 Aug 2015)
• MEB US Broker Report (17 Aug 2015)
• MEB US Update (17 Aug 2015)
• MEB Completes Development of Corporate Stress Product (21 Aug 2015)
• MEB First Commercial Deal (27 August 2015)
• MEB Investor Presentation (August 2015)

• Medibio Ltd processes first participant in UNSW depression test validation study (11 May 2015)
• March Quarterly Activities Report (13 May 2015)
• MEB Preventice MOU Release (28 May 2015)
• Medibio Press Article (May 2015)

• U.S. Depression market size (6 Feb 2015)
• Medibio Limited Health Stage 1 Program

• BPO Share Issue Cleansing Statement
• BPO Trading Halt Request correction
• BPO ASX Release Name Change
• BPO ASX Release AGM Results
• BPO Appendix 3B B Kay Taurus C Note Share Issue revised
• BPO ASX Release MJP Appointment approved for release
• BPO ASX Release BDI Study

• Change of Director’s Interest Notice
• BPO Responds to Explosive Demand for E-Health Consumer Prod
• Change in substantial Holding
• Change of Director’s Interest Notice

• Successful Completion of Technical Due Diligence
• Appendix 4D

• Expiry of Options
• Investor Presentation Invatec
• Expiry of Options
• Cleansing Statement
• Appendix 3B
• Options to acquire Depression Diagnostic Project